JP5355561B2 - 生物活性ペプチドおよびその使用方法 - Google Patents
生物活性ペプチドおよびその使用方法 Download PDFInfo
- Publication number
- JP5355561B2 JP5355561B2 JP2010515627A JP2010515627A JP5355561B2 JP 5355561 B2 JP5355561 B2 JP 5355561B2 JP 2010515627 A JP2010515627 A JP 2010515627A JP 2010515627 A JP2010515627 A JP 2010515627A JP 5355561 B2 JP5355561 B2 JP 5355561B2
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- seq
- amide
- disease
- peptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 512
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 190
- 238000000034 method Methods 0.000 title description 136
- 239000002253 acid Substances 0.000 claims description 79
- 239000003814 drug Substances 0.000 claims description 55
- 150000001408 amides Chemical class 0.000 claims description 53
- 241000282414 Homo sapiens Species 0.000 claims description 42
- 229920001184 polypeptide Polymers 0.000 claims description 42
- 229940124597 therapeutic agent Drugs 0.000 claims description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 241000282693 Cercopithecidae Species 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 230000002285 radioactive effect Effects 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 239000007850 fluorescent dye Substances 0.000 claims description 3
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract description 62
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract description 62
- 230000004913 activation Effects 0.000 abstract description 31
- 239000003446 ligand Substances 0.000 abstract description 22
- 210000004027 cell Anatomy 0.000 description 136
- 229940024606 amino acid Drugs 0.000 description 127
- 235000001014 amino acid Nutrition 0.000 description 126
- 150000001413 amino acids Chemical class 0.000 description 120
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 117
- 201000010099 disease Diseases 0.000 description 81
- 108090000103 Relaxin Proteins 0.000 description 77
- 102000003743 Relaxin Human genes 0.000 description 76
- 101000869643 Homo sapiens Relaxin receptor 1 Proteins 0.000 description 70
- 102100032444 Relaxin receptor 1 Human genes 0.000 description 70
- 230000000694 effects Effects 0.000 description 68
- 238000011282 treatment Methods 0.000 description 66
- 108090000623 proteins and genes Proteins 0.000 description 55
- 102000004169 proteins and genes Human genes 0.000 description 51
- 235000018102 proteins Nutrition 0.000 description 50
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 48
- 239000000203 mixture Substances 0.000 description 47
- -1 cyclic lactam Chemical class 0.000 description 41
- 101000869654 Homo sapiens Relaxin receptor 2 Proteins 0.000 description 40
- 102100032445 Relaxin receptor 2 Human genes 0.000 description 40
- 230000002209 hydrophobic effect Effects 0.000 description 40
- 206010016654 Fibrosis Diseases 0.000 description 39
- 206010028980 Neoplasm Diseases 0.000 description 32
- 201000011510 cancer Diseases 0.000 description 31
- 230000004761 fibrosis Effects 0.000 description 31
- 238000001994 activation Methods 0.000 description 30
- 206010019280 Heart failures Diseases 0.000 description 28
- 206010020772 Hypertension Diseases 0.000 description 28
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 28
- 239000002502 liposome Substances 0.000 description 28
- 102000005962 receptors Human genes 0.000 description 26
- 108020003175 receptors Proteins 0.000 description 26
- 210000001519 tissue Anatomy 0.000 description 26
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 24
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 24
- 208000010125 myocardial infarction Diseases 0.000 description 24
- 230000035935 pregnancy Effects 0.000 description 24
- 108060003951 Immunoglobulin Proteins 0.000 description 23
- 206010063837 Reperfusion injury Diseases 0.000 description 23
- 102000018358 immunoglobulin Human genes 0.000 description 23
- 230000001965 increasing effect Effects 0.000 description 23
- 102100033262 Insulin-like 3 Human genes 0.000 description 22
- 210000003169 central nervous system Anatomy 0.000 description 22
- 229940079593 drug Drugs 0.000 description 22
- 208000017169 kidney disease Diseases 0.000 description 22
- 206010007559 Cardiac failure congestive Diseases 0.000 description 21
- 102100022105 Relaxin-3 receptor 1 Human genes 0.000 description 21
- 125000000539 amino acid group Chemical group 0.000 description 21
- 208000035475 disorder Diseases 0.000 description 21
- 230000004048 modification Effects 0.000 description 21
- 238000012986 modification Methods 0.000 description 21
- 238000011068 loading method Methods 0.000 description 19
- 101001110357 Homo sapiens Relaxin-3 receptor 1 Proteins 0.000 description 18
- 102100031036 Leucine-rich repeat-containing G-protein coupled receptor 5 Human genes 0.000 description 18
- 102000037126 Leucine-rich repeat-containing G-protein-coupled receptors Human genes 0.000 description 18
- 108091006332 Leucine-rich repeat-containing G-protein-coupled receptors Proteins 0.000 description 18
- 206010012601 diabetes mellitus Diseases 0.000 description 18
- 229920000642 polymer Polymers 0.000 description 18
- 239000013641 positive control Substances 0.000 description 18
- 102000008186 Collagen Human genes 0.000 description 17
- 108010035532 Collagen Proteins 0.000 description 17
- 101001063456 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 description 17
- 229920001436 collagen Polymers 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 17
- 238000009472 formulation Methods 0.000 description 17
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 201000005569 Gout Diseases 0.000 description 16
- 102100031035 Leucine-rich repeat-containing G-protein coupled receptor 4 Human genes 0.000 description 16
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 16
- 125000003275 alpha amino acid group Chemical group 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 16
- 210000000056 organ Anatomy 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 208000019693 Lung disease Diseases 0.000 description 15
- 210000000988 bone and bone Anatomy 0.000 description 15
- 231100000673 dose–response relationship Toxicity 0.000 description 15
- 230000013595 glycosylation Effects 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 15
- 208000014674 injury Diseases 0.000 description 15
- 230000002093 peripheral effect Effects 0.000 description 15
- 208000024172 Cardiovascular disease Diseases 0.000 description 14
- 101001063463 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 4 Proteins 0.000 description 14
- 101000981765 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 6 Proteins 0.000 description 14
- 102100024140 Leucine-rich repeat-containing G-protein coupled receptor 6 Human genes 0.000 description 14
- 206010039710 Scleroderma Diseases 0.000 description 14
- 238000006206 glycosylation reaction Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 230000029663 wound healing Effects 0.000 description 14
- 206010009900 Colitis ulcerative Diseases 0.000 description 13
- 208000012322 Raynaud phenomenon Diseases 0.000 description 13
- 201000006704 Ulcerative Colitis Diseases 0.000 description 13
- 230000033115 angiogenesis Effects 0.000 description 13
- SCJNCDSAIRBRIA-DOFZRALJSA-N arachidonyl-2'-chloroethylamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCCl SCJNCDSAIRBRIA-DOFZRALJSA-N 0.000 description 13
- 230000007423 decrease Effects 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 208000023275 Autoimmune disease Diseases 0.000 description 12
- 101001039035 Homo sapiens Lutropin-choriogonadotropic hormone receptor Proteins 0.000 description 12
- 102100040788 Lutropin-choriogonadotropic hormone receptor Human genes 0.000 description 12
- 208000006011 Stroke Diseases 0.000 description 12
- 230000002159 abnormal effect Effects 0.000 description 12
- 238000007792 addition Methods 0.000 description 12
- 125000003118 aryl group Chemical group 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 208000006673 asthma Diseases 0.000 description 12
- 230000015556 catabolic process Effects 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 239000003623 enhancer Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 208000027866 inflammatory disease Diseases 0.000 description 12
- 208000028867 ischemia Diseases 0.000 description 12
- 230000000302 ischemic effect Effects 0.000 description 12
- 210000003734 kidney Anatomy 0.000 description 12
- 229920001223 polyethylene glycol Polymers 0.000 description 12
- 230000002265 prevention Effects 0.000 description 12
- 206010039073 rheumatoid arthritis Diseases 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 12
- 210000001550 testis Anatomy 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 12
- 206010009944 Colon cancer Diseases 0.000 description 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 11
- 208000011231 Crohn disease Diseases 0.000 description 11
- 208000007536 Thrombosis Diseases 0.000 description 11
- 208000036142 Viral infection Diseases 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 206010003246 arthritis Diseases 0.000 description 11
- 238000009739 binding Methods 0.000 description 11
- 150000001720 carbohydrates Chemical group 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 208000019425 cirrhosis of liver Diseases 0.000 description 11
- 208000029078 coronary artery disease Diseases 0.000 description 11
- 238000006731 degradation reaction Methods 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 230000000638 stimulation Effects 0.000 description 11
- 238000001356 surgical procedure Methods 0.000 description 11
- 230000024883 vasodilation Effects 0.000 description 11
- 230000009385 viral infection Effects 0.000 description 11
- 102000055006 Calcitonin Human genes 0.000 description 10
- 108060001064 Calcitonin Proteins 0.000 description 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 10
- 208000001132 Osteoporosis Diseases 0.000 description 10
- 239000002202 Polyethylene glycol Substances 0.000 description 10
- 102100022100 Relaxin-3 receptor 2 Human genes 0.000 description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 10
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 10
- 229960004015 calcitonin Drugs 0.000 description 10
- 235000014633 carbohydrates Nutrition 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 10
- 239000003094 microcapsule Substances 0.000 description 10
- 239000000816 peptidomimetic Substances 0.000 description 10
- 201000011461 pre-eclampsia Diseases 0.000 description 10
- 238000007634 remodeling Methods 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 9
- 206010048554 Endothelial dysfunction Diseases 0.000 description 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 9
- 201000004681 Psoriasis Diseases 0.000 description 9
- 208000012931 Urologic disease Diseases 0.000 description 9
- 230000001593 cAMP accumulation Effects 0.000 description 9
- 230000003436 cytoskeletal effect Effects 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 229910003460 diamond Inorganic materials 0.000 description 9
- 239000010432 diamond Substances 0.000 description 9
- 238000005538 encapsulation Methods 0.000 description 9
- 230000008694 endothelial dysfunction Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 238000001415 gene therapy Methods 0.000 description 9
- 229940072221 immunoglobulins Drugs 0.000 description 9
- 230000004968 inflammatory condition Effects 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 201000006417 multiple sclerosis Diseases 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 208000023504 respiratory system disease Diseases 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 208000014001 urinary system disease Diseases 0.000 description 9
- 210000005166 vasculature Anatomy 0.000 description 9
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 8
- 208000010228 Erectile Dysfunction Diseases 0.000 description 8
- 208000007882 Gastritis Diseases 0.000 description 8
- 206010018634 Gouty Arthritis Diseases 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 8
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 8
- KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 8
- 208000008589 Obesity Diseases 0.000 description 8
- 208000018262 Peripheral vascular disease Diseases 0.000 description 8
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 8
- 208000025865 Ulcer Diseases 0.000 description 8
- 125000003277 amino group Chemical group 0.000 description 8
- 230000007882 cirrhosis Effects 0.000 description 8
- 239000000835 fiber Substances 0.000 description 8
- 210000002216 heart Anatomy 0.000 description 8
- 201000001881 impotence Diseases 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- 201000001119 neuropathy Diseases 0.000 description 8
- 230000007823 neuropathy Effects 0.000 description 8
- 235000020824 obesity Nutrition 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 230000001850 reproductive effect Effects 0.000 description 8
- 208000037803 restenosis Diseases 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 230000021595 spermatogenesis Effects 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- 230000008733 trauma Effects 0.000 description 8
- 231100000397 ulcer Toxicity 0.000 description 8
- 206010002383 Angina Pectoris Diseases 0.000 description 7
- 208000014181 Bronchial disease Diseases 0.000 description 7
- 229920000858 Cyclodextrin Polymers 0.000 description 7
- 201000003883 Cystic fibrosis Diseases 0.000 description 7
- 101001110356 Homo sapiens Relaxin-3 receptor 2 Proteins 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
- 208000025609 Urogenital disease Diseases 0.000 description 7
- 229940000635 beta-alanine Drugs 0.000 description 7
- 230000000975 bioactive effect Effects 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 238000007385 chemical modification Methods 0.000 description 7
- 238000002648 combination therapy Methods 0.000 description 7
- 210000002808 connective tissue Anatomy 0.000 description 7
- 238000013270 controlled release Methods 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 230000007937 eating Effects 0.000 description 7
- 229940011871 estrogen Drugs 0.000 description 7
- 239000000262 estrogen Substances 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 150000007523 nucleic acids Chemical group 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000037390 scarring Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000017423 tissue regeneration Effects 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- 208000003174 Brain Neoplasms Diseases 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- 208000007984 Female Infertility Diseases 0.000 description 6
- 102100027627 Follicle-stimulating hormone receptor Human genes 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 101000862396 Homo sapiens Follicle-stimulating hormone receptor Proteins 0.000 description 6
- 101000772267 Homo sapiens Thyrotropin receptor Proteins 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 206010021928 Infertility female Diseases 0.000 description 6
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 description 6
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- 206010025323 Lymphomas Diseases 0.000 description 6
- 208000007466 Male Infertility Diseases 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 206010033128 Ovarian cancer Diseases 0.000 description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 6
- 208000031481 Pathologic Constriction Diseases 0.000 description 6
- 206010060862 Prostate cancer Diseases 0.000 description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 6
- 208000003782 Raynaud disease Diseases 0.000 description 6
- 102100034944 Relaxin-3 Human genes 0.000 description 6
- 101710113452 Relaxin-3 Proteins 0.000 description 6
- 206010038389 Renal cancer Diseases 0.000 description 6
- 206010039491 Sarcoma Diseases 0.000 description 6
- 239000004473 Threonine Substances 0.000 description 6
- 102100029337 Thyrotropin receptor Human genes 0.000 description 6
- 206010047115 Vasculitis Diseases 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 208000026106 cerebrovascular disease Diseases 0.000 description 6
- 208000029742 colonic neoplasm Diseases 0.000 description 6
- 229940097362 cyclodextrins Drugs 0.000 description 6
- 230000008021 deposition Effects 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 230000002357 endometrial effect Effects 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 239000002532 enzyme inhibitor Substances 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 201000010982 kidney cancer Diseases 0.000 description 6
- 201000005202 lung cancer Diseases 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- 206010025135 lupus erythematosus Diseases 0.000 description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 6
- 238000007726 management method Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 230000015654 memory Effects 0.000 description 6
- 208000030159 metabolic disease Diseases 0.000 description 6
- 208000037819 metastatic cancer Diseases 0.000 description 6
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 6
- 230000001613 neoplastic effect Effects 0.000 description 6
- 201000008482 osteoarthritis Diseases 0.000 description 6
- 201000002528 pancreatic cancer Diseases 0.000 description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 208000033808 peripheral neuropathy Diseases 0.000 description 6
- 210000002826 placenta Anatomy 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 6
- 230000036262 stenosis Effects 0.000 description 6
- 208000037804 stenosis Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 5
- 206010003210 Arteriosclerosis Diseases 0.000 description 5
- 101150006300 CALCR gene Proteins 0.000 description 5
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 5
- 201000009273 Endometriosis Diseases 0.000 description 5
- 102000016359 Fibronectins Human genes 0.000 description 5
- 108010067306 Fibronectins Proteins 0.000 description 5
- 102000038630 GPCRs class A Human genes 0.000 description 5
- 108091007907 GPCRs class A Proteins 0.000 description 5
- 208000010412 Glaucoma Diseases 0.000 description 5
- 206010061216 Infarction Diseases 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 208000009525 Myocarditis Diseases 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 5
- 206010040047 Sepsis Diseases 0.000 description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
- 206010052779 Transplant rejections Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 210000004100 adrenal gland Anatomy 0.000 description 5
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 5
- 235000010443 alginic acid Nutrition 0.000 description 5
- 229920000615 alginic acid Polymers 0.000 description 5
- 239000000783 alginic acid Substances 0.000 description 5
- 229960001126 alginic acid Drugs 0.000 description 5
- 150000004781 alginic acids Chemical class 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 description 5
- 239000012867 bioactive agent Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000001149 cognitive effect Effects 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 206010020718 hyperplasia Diseases 0.000 description 5
- 230000002390 hyperplastic effect Effects 0.000 description 5
- 230000007574 infarction Effects 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 201000008968 osteosarcoma Diseases 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 210000002307 prostate Anatomy 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
- 208000019553 vascular disease Diseases 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 4
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 4
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 4
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 4
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 4
- 208000020084 Bone disease Diseases 0.000 description 4
- 206010012438 Dermatitis atopic Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 108091006027 G proteins Proteins 0.000 description 4
- 102000030782 GTP binding Human genes 0.000 description 4
- 108091000058 GTP-Binding Proteins 0.000 description 4
- 101001091088 Homo sapiens Prorelaxin H2 Proteins 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 4
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 201000002481 Myositis Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 102100034949 Prorelaxin H2 Human genes 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 208000028990 Skin injury Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 description 4
- 206010057644 Testis cancer Diseases 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 206010047139 Vasoconstriction Diseases 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000010933 acylation Effects 0.000 description 4
- 238000005917 acylation reaction Methods 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 208000021328 arterial occlusion Diseases 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- 229920002988 biodegradable polymer Polymers 0.000 description 4
- 239000004621 biodegradable polymer Substances 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 210000004534 cecum Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 208000010877 cognitive disease Diseases 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000001212 derivatisation Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 230000008482 dysregulation Effects 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000001476 gene delivery Methods 0.000 description 4
- 210000002149 gonad Anatomy 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 208000037805 labour Diseases 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 208000031225 myocardial ischemia Diseases 0.000 description 4
- 208000011851 neurological alteration Diseases 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 230000005070 ripening Effects 0.000 description 4
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 4
- 201000000980 schizophrenia Diseases 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 230000037380 skin damage Effects 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000011191 terminal modification Methods 0.000 description 4
- 201000003120 testicular cancer Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000001685 thyroid gland Anatomy 0.000 description 4
- 230000007838 tissue remodeling Effects 0.000 description 4
- 230000025033 vasoconstriction Effects 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 description 3
- 206010001029 Acute pulmonary oedema Diseases 0.000 description 3
- 208000026872 Addison Disease Diseases 0.000 description 3
- 208000007848 Alcoholism Diseases 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 206010003658 Atrial Fibrillation Diseases 0.000 description 3
- 208000004300 Atrophic Gastritis Diseases 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 208000023328 Basedow disease Diseases 0.000 description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 3
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 3
- 206010005949 Bone cancer Diseases 0.000 description 3
- 208000018084 Bone neoplasm Diseases 0.000 description 3
- 206010006458 Bronchitis chronic Diseases 0.000 description 3
- 206010006895 Cachexia Diseases 0.000 description 3
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 3
- 208000031229 Cardiomyopathies Diseases 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 208000028698 Cognitive impairment Diseases 0.000 description 3
- 208000027932 Collagen disease Diseases 0.000 description 3
- 241000711573 Coronaviridae Species 0.000 description 3
- 102000001189 Cyclic Peptides Human genes 0.000 description 3
- 108010069514 Cyclic Peptides Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 241000725619 Dengue virus Species 0.000 description 3
- 206010012335 Dependence Diseases 0.000 description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 3
- 241000709661 Enterovirus Species 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 208000036495 Gastritis atrophic Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 102000034354 Gi proteins Human genes 0.000 description 3
- 108091006101 Gi proteins Proteins 0.000 description 3
- 208000032612 Glial tumor Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 208000024869 Goodpasture syndrome Diseases 0.000 description 3
- 208000015023 Graves' disease Diseases 0.000 description 3
- 206010061192 Haemorrhagic fever Diseases 0.000 description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 3
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 206010020850 Hyperthyroidism Diseases 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 3
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 3
- 208000024934 IgG4-related mediastinitis Diseases 0.000 description 3
- 208000005168 Intussusception Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 208000003456 Juvenile Arthritis Diseases 0.000 description 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- 150000008575 L-amino acids Chemical class 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 208000020358 Learning disease Diseases 0.000 description 3
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 208000002805 Mediastinal fibrosis Diseases 0.000 description 3
- 208000026139 Memory disease Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 3
- 241000714177 Murine leukemia virus Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000007101 Muscle Cramp Diseases 0.000 description 3
- 206010028665 Myxoedema Diseases 0.000 description 3
- 206010029113 Neovascularisation Diseases 0.000 description 3
- 230000004989 O-glycosylation Effects 0.000 description 3
- 208000026251 Opioid-Related disease Diseases 0.000 description 3
- 206010053159 Organ failure Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 241000721454 Pemphigus Species 0.000 description 3
- 208000031845 Pernicious anaemia Diseases 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 206010036030 Polyarthritis Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 3
- 101710117864 Relaxin-3 receptor 1 Proteins 0.000 description 3
- 101710117881 Relaxin-3 receptor 2 Proteins 0.000 description 3
- 208000033626 Renal failure acute Diseases 0.000 description 3
- 206010062237 Renal impairment Diseases 0.000 description 3
- 208000007135 Retinal Neovascularization Diseases 0.000 description 3
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- 201000001880 Sexual dysfunction Diseases 0.000 description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 3
- 244000061456 Solanum tuberosum Species 0.000 description 3
- 235000002595 Solanum tuberosum Nutrition 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 201000009594 Systemic Scleroderma Diseases 0.000 description 3
- 206010042953 Systemic sclerosis Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 208000026723 Urinary tract disease Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 206010053648 Vascular occlusion Diseases 0.000 description 3
- 206010047141 Vasodilatation Diseases 0.000 description 3
- 201000006449 West Nile encephalitis Diseases 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 238000006640 acetylation reaction Methods 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 201000011040 acute kidney failure Diseases 0.000 description 3
- 206010069351 acute lung injury Diseases 0.000 description 3
- 208000012998 acute renal failure Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000009435 amidation Effects 0.000 description 3
- 238000007112 amidation reaction Methods 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000002583 angiography Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 230000002785 anti-thrombosis Effects 0.000 description 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 235000021407 appetite control Nutrition 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 3
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 3
- 201000004982 autoimmune uveitis Diseases 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 229920000249 biocompatible polymer Polymers 0.000 description 3
- 208000029162 bladder disease Diseases 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 230000002308 calcification Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000009787 cardiac fibrosis Effects 0.000 description 3
- 230000002612 cardiopulmonary effect Effects 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 230000035606 childbirth Effects 0.000 description 3
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 3
- 208000007451 chronic bronchitis Diseases 0.000 description 3
- 208000019069 chronic childhood arthritis Diseases 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000007585 cortical function Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 201000001981 dermatomyositis Diseases 0.000 description 3
- 208000033679 diabetic kidney disease Diseases 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000006471 dimerization reaction Methods 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 230000004590 drinking behavior Effects 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 206010013663 drug dependence Diseases 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000020595 eating behavior Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000003073 embolic effect Effects 0.000 description 3
- 230000013020 embryo development Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 208000030533 eye disease Diseases 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 208000011404 female reproductive system disease Diseases 0.000 description 3
- 230000004720 fertilization Effects 0.000 description 3
- 206010016629 fibroma Diseases 0.000 description 3
- 206010049444 fibromatosis Diseases 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 206010061989 glomerulosclerosis Diseases 0.000 description 3
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
- 201000010536 head and neck cancer Diseases 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 230000009610 hypersensitivity Effects 0.000 description 3
- 208000015210 hypertensive heart disease Diseases 0.000 description 3
- 230000036543 hypotension Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 3
- 230000005977 kidney dysfunction Effects 0.000 description 3
- 201000003723 learning disability Diseases 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 208000006132 lipodystrophy Diseases 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000001926 lymphatic effect Effects 0.000 description 3
- 208000002780 macular degeneration Diseases 0.000 description 3
- 210000004995 male reproductive system Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000004579 marble Substances 0.000 description 3
- 231100000551 menstrual abnormality Toxicity 0.000 description 3
- 210000003975 mesenteric artery Anatomy 0.000 description 3
- 210000001758 mesenteric vein Anatomy 0.000 description 3
- 230000006371 metabolic abnormality Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 206010028417 myasthenia gravis Diseases 0.000 description 3
- 208000037891 myocardial injury Diseases 0.000 description 3
- 208000003786 myxedema Diseases 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 201000008383 nephritis Diseases 0.000 description 3
- 230000004112 neuroprotection Effects 0.000 description 3
- 230000015277 nipple development Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 201000005040 opiate dependence Diseases 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000006320 pegylation Effects 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 208000027232 peripheral nervous system disease Diseases 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000028742 placenta development Effects 0.000 description 3
- 208000005987 polymyositis Diseases 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 description 3
- 208000002815 pulmonary hypertension Diseases 0.000 description 3
- 206010038464 renal hypertension Diseases 0.000 description 3
- 230000008521 reorganization Effects 0.000 description 3
- 201000003068 rheumatic fever Diseases 0.000 description 3
- 230000036303 septic shock Effects 0.000 description 3
- 231100000872 sexual dysfunction Toxicity 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 201000009890 sinusitis Diseases 0.000 description 3
- 208000019116 sleep disease Diseases 0.000 description 3
- 208000020685 sleep-wake disease Diseases 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 230000019100 sperm motility Effects 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 201000009032 substance abuse Diseases 0.000 description 3
- 208000011117 substance-related disease Diseases 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 208000037905 systemic hypertension Diseases 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001732 thrombotic effect Effects 0.000 description 3
- 230000009092 tissue dysfunction Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 208000026533 urinary bladder disease Diseases 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 208000021331 vascular occlusion disease Diseases 0.000 description 3
- 229940124549 vasodilator Drugs 0.000 description 3
- 239000003071 vasodilator agent Substances 0.000 description 3
- 230000009278 visceral effect Effects 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 2
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- KSWRZJNADSIDKV-UHFFFAOYSA-N 8-amino-3-hydroxynaphthalene-1,6-disulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=C2C(N)=CC(S(O)(=O)=O)=CC2=C1 KSWRZJNADSIDKV-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 200000000007 Arterial disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 101710137926 Chymotrypsin inhibitor Proteins 0.000 description 2
- 229940122644 Chymotrypsin inhibitor Drugs 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 2
- 208000003037 Diastolic Heart Failure Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229910052693 Europium Inorganic materials 0.000 description 2
- 206010015943 Eye inflammation Diseases 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 208000022555 Genital disease Diseases 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 2
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 102100033266 Insulin-like peptide INSL5 Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 102000000853 LDL receptors Human genes 0.000 description 2
- 108010001831 LDL receptors Proteins 0.000 description 2
- 208000019395 Lactation disease Diseases 0.000 description 2
- 101710174259 Leucine-rich repeat-containing G-protein coupled receptor 4 Proteins 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010027727 Mitral valve incompetence Diseases 0.000 description 2
- 206010028594 Myocardial fibrosis Diseases 0.000 description 2
- DTERQYGMUDWYAZ-ZETCQYMHSA-N N(6)-acetyl-L-lysine Chemical compound CC(=O)NCCCC[C@H]([NH3+])C([O-])=O DTERQYGMUDWYAZ-ZETCQYMHSA-N 0.000 description 2
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000008826 Obstetric Labor Complications Diseases 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229920001273 Polyhydroxy acid Polymers 0.000 description 2
- 208000005107 Premature Birth Diseases 0.000 description 2
- 206010036590 Premature baby Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 206010038926 Retinopathy hypertensive Diseases 0.000 description 2
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 2
- 108010077895 Sarcosine Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 206010072207 Splenic fibrosis Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 2
- 206010043647 Thrombotic Stroke Diseases 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WTOFYLAWDLQMBZ-LURJTMIESA-N beta(2-thienyl)alanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CS1 WTOFYLAWDLQMBZ-LURJTMIESA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000009992 cAMP activation Effects 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000007675 cardiac surgery Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003541 chymotrypsin inhibitor Substances 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 235000013477 citrulline Nutrition 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 229920001577 copolymer Chemical class 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 230000022811 deglycosylation Effects 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 230000004406 elevated intraocular pressure Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000004696 endometrium Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 208000010227 enterocolitis Diseases 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
- 210000004996 female reproductive system Anatomy 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229960005051 fluostigmine Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 201000001948 hypertensive retinopathy Diseases 0.000 description 2
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 210000000713 mesentery Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 208000005907 mitral valve insufficiency Diseases 0.000 description 2
- 230000004682 mucosal barrier function Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000003961 penetration enhancing agent Substances 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 2
- OAHKWDDSKCRNFE-UHFFFAOYSA-N phenylmethanesulfonyl chloride Chemical compound ClS(=O)(=O)CC1=CC=CC=C1 OAHKWDDSKCRNFE-UHFFFAOYSA-N 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 208000007232 portal hypertension Diseases 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 229940043230 sarcosine Drugs 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 208000022610 schizoaffective disease Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 150000003408 sphingolipids Chemical class 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000000365 steroidogenetic effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 150000007968 uric acids Chemical class 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000006492 vascular dysfunction Effects 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 1
- RWLSBXBFZHDHHX-VIFPVBQESA-N (2s)-2-(naphthalen-2-ylamino)propanoic acid Chemical compound C1=CC=CC2=CC(N[C@@H](C)C(O)=O)=CC=C21 RWLSBXBFZHDHHX-VIFPVBQESA-N 0.000 description 1
- KYBXNPIASYUWLN-WUCPZUCCSA-N (2s)-5-hydroxypyrrolidine-2-carboxylic acid Chemical compound OC1CC[C@@H](C(O)=O)N1 KYBXNPIASYUWLN-WUCPZUCCSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- BWKMGYQJPOAASG-UHFFFAOYSA-M 1,2,3,4-tetrahydroisoquinoline-3-carboxylate Chemical compound C1=CC=C2CNC(C(=O)[O-])CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-M 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- MPBMJFQAGBVIDC-UHFFFAOYSA-N 1-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2C(O)NC(C(O)=O)CC2=C1 MPBMJFQAGBVIDC-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- KYWCUACNBIYDNL-UHFFFAOYSA-N 1-oxo-2h-isoquinoline-3-carboxylic acid Chemical compound C1=CC=C2C(=O)NC(C(=O)O)=CC2=C1 KYWCUACNBIYDNL-UHFFFAOYSA-N 0.000 description 1
- 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- DCESWPKOLYIMNH-UHFFFAOYSA-N 2-(2,5-dioxopyrrolidin-1-yl)propanoic acid Chemical compound OC(=O)C(C)N1C(=O)CCC1=O DCESWPKOLYIMNH-UHFFFAOYSA-N 0.000 description 1
- BHANCCMWYDZQOR-UHFFFAOYSA-N 2-(methyldisulfanyl)pyridine Chemical compound CSSC1=CC=CC=N1 BHANCCMWYDZQOR-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- OFYAYGJCPXRNBL-UHFFFAOYSA-N 2-azaniumyl-3-naphthalen-1-ylpropanoate Chemical compound C1=CC=C2C(CC(N)C(O)=O)=CC=CC2=C1 OFYAYGJCPXRNBL-UHFFFAOYSA-N 0.000 description 1
- FKJSFKCZZIXQIP-UHFFFAOYSA-N 2-bromo-1-(4-bromophenyl)ethanone Chemical compound BrCC(=O)C1=CC=C(Br)C=C1 FKJSFKCZZIXQIP-UHFFFAOYSA-N 0.000 description 1
- JQPFYXFVUKHERX-UHFFFAOYSA-N 2-hydroxy-2-cyclohexen-1-one Natural products OC1=CCCCC1=O JQPFYXFVUKHERX-UHFFFAOYSA-N 0.000 description 1
- 229940044192 2-hydroxyethyl methacrylate Drugs 0.000 description 1
- VJINKBZUJYGZGP-UHFFFAOYSA-N 3-(1-aminopropylideneamino)propyl-trimethylazanium Chemical compound CCC(N)=NCCC[N+](C)(C)C VJINKBZUJYGZGP-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- BIGBDMFRWJRLGJ-UHFFFAOYSA-N 3-benzyl-1,5-didiazoniopenta-1,4-diene-2,4-diolate Chemical compound [N-]=[N+]=CC(=O)C(C(=O)C=[N+]=[N-])CC1=CC=CC=C1 BIGBDMFRWJRLGJ-UHFFFAOYSA-N 0.000 description 1
- ONZQYZKCUHFORE-UHFFFAOYSA-N 3-bromo-1,1,1-trifluoropropan-2-one Chemical compound FC(F)(F)C(=O)CBr ONZQYZKCUHFORE-UHFFFAOYSA-N 0.000 description 1
- QHSXWDVVFHXHHB-UHFFFAOYSA-N 3-nitro-2-[(3-nitropyridin-2-yl)disulfanyl]pyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1SSC1=NC=CC=C1[N+]([O-])=O QHSXWDVVFHXHHB-UHFFFAOYSA-N 0.000 description 1
- NLPWSMKACWGINL-UHFFFAOYSA-N 4-azido-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(N=[N+]=[N-])C=C1O NLPWSMKACWGINL-UHFFFAOYSA-N 0.000 description 1
- XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- BJRCFZKVYNDCJE-WBSNEMHCSA-N 99489-95-9 Chemical compound C([C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)NCC(=O)N2)[C@@H](C)CC)=O)CSSC[C@@H](C(NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC1=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)C(C)C)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCCCN)C(C)C)[C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCNC(N)=N)C(C)C)C1=CC=C(O)C=C1 BJRCFZKVYNDCJE-WBSNEMHCSA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920006051 Capron® Polymers 0.000 description 1
- 102100037355 Chromosome alignment-maintaining phosphoprotein 1 Human genes 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102100025892 Complement C1q tumor necrosis factor-related protein 1 Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 206010011498 Cryptorchism Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- 229930195711 D-Serine Natural products 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100033267 Early placenta insulin-like peptide Human genes 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102100033837 G-protein coupled receptor 135 Human genes 0.000 description 1
- 102100030280 G-protein coupled receptor 39 Human genes 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101000741320 Homo sapiens Cathelicidin antimicrobial peptide Proteins 0.000 description 1
- 101000880066 Homo sapiens Chromosome alignment-maintaining phosphoprotein 1 Proteins 0.000 description 1
- 101000933670 Homo sapiens Complement C1q tumor necrosis factor-related protein 1 Proteins 0.000 description 1
- 101000996783 Homo sapiens G-protein coupled receptor 135 Proteins 0.000 description 1
- 101001009541 Homo sapiens G-protein coupled receptor 39 Proteins 0.000 description 1
- 101000998774 Homo sapiens Insulin-like peptide INSL5 Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102100033235 Insulin-like peptide INSL6 Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- FYSKZKQBTVLYEQ-FSLKYBNLSA-N Kallidin Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 FYSKZKQBTVLYEQ-FSLKYBNLSA-N 0.000 description 1
- 108010003195 Kallidin Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 101710174256 Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 description 1
- 108700014400 Leydig insulin-like Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010064584 Myosclerosis Diseases 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- VIHYIVKEECZGOU-UHFFFAOYSA-N N-acetylimidazole Chemical compound CC(=O)N1C=CN=C1 VIHYIVKEECZGOU-UHFFFAOYSA-N 0.000 description 1
- 230000006181 N-acylation Effects 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 101710126321 Pancreatic trypsin inhibitor Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 229930182556 Polyacetal Natural products 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 229920001963 Synthetic biodegradable polymer Polymers 0.000 description 1
- 208000008253 Systolic Heart Failure Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000011622 Testicular disease Diseases 0.000 description 1
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 1
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100030018 Tumor protein p73 Human genes 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 208000033774 Ventricular Remodeling Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001294 alanine derivatives Chemical class 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 238000005905 alkynylation reaction Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000006242 amine protecting group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 229940124538 antidiuretic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 229920000229 biodegradable polyester Polymers 0.000 description 1
- 239000004622 biodegradable polyester Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 201000008873 bone osteosarcoma Diseases 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000013262 cAMP assay Methods 0.000 description 1
- 230000001201 calcium accumulation Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbamic acid group Chemical group C(N)(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- JLQUFIHWVLZVTJ-UHFFFAOYSA-N carbosulfan Chemical compound CCCCN(CCCC)SN(C)C(=O)OC1=CC=CC2=C1OC(C)(C)C2 JLQUFIHWVLZVTJ-UHFFFAOYSA-N 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 125000006244 carboxylic acid protecting group Chemical group 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000001159 caudate nucleus Anatomy 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- 150000001784 cerebrosides Chemical class 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 210000003467 cheek Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000002779 cholinesterase reactivator Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 201000000160 cryptorchidism Diseases 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- OILAIQUEIWYQPH-UHFFFAOYSA-N cyclohexane-1,2-dione Chemical compound O=C1CCCCC1=O OILAIQUEIWYQPH-UHFFFAOYSA-N 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 150000002190 fatty acyls Chemical class 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 125000005439 maleimidyl group Chemical class C1(C=CC(N1*)=O)=O 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002905 metal composite material Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- RMAHPRNLQIRHIJ-UHFFFAOYSA-N methyl carbamimidate Chemical compound COC(N)=N RMAHPRNLQIRHIJ-UHFFFAOYSA-N 0.000 description 1
- NEGQCMNHXHSFGU-UHFFFAOYSA-N methyl pyridine-2-carboximidate Chemical compound COC(=N)C1=CC=CC=N1 NEGQCMNHXHSFGU-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000006082 mold release agent Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000004677 mucosal permeability Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- YFZOUMNUDGGHIW-UHFFFAOYSA-M p-chloromercuribenzoic acid Chemical compound OC(=O)C1=CC=C([Hg]Cl)C=C1 YFZOUMNUDGGHIW-UHFFFAOYSA-M 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- 150000003904 phospholipids Chemical group 0.000 description 1
- HMFAQQIORZDPJG-UHFFFAOYSA-N phosphono 2-chloroacetate Chemical compound OP(O)(=O)OC(=O)CCl HMFAQQIORZDPJG-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000083 poly(allylamine) Polymers 0.000 description 1
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000012495 positive regulation of renal sodium excretion Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000003689 pubic bone Anatomy 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229920013730 reactive polymer Polymers 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 210000000574 retroperitoneal space Anatomy 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical group OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 125000005624 silicic acid group Chemical class 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000001300 stimulation of adenylate cyclase Effects 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 238000005987 sulfurization reaction Methods 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- NPDBDJFLKKQMCM-UHFFFAOYSA-N tert-butylglycine Chemical compound CC(C)(C)C(N)C(O)=O NPDBDJFLKKQMCM-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000014723 transformation of host cell by virus Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 108010080050 trypsin drug combination chymotrypsin Proteins 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- JPZXHKDZASGCLU-LBPRGKRZSA-N β-(2-naphthyl)-alanine Chemical compound C1=CC=CC2=CC(C[C@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-LBPRGKRZSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
Description
ペプチドP59−S−アミド(アミド):AYAAFSV−アミド(配列番号:1);
ペプチドP59−SG(遊離酸Gly):AYAAFSV(配列番号:2);
ペプチドP59−アミド(アミド):GQKGQVGPPGAACRRAYAAFSV−アミド(配列番号:3);
ペプチドP59(遊離酸):GQKGQVGPPGAACRRAYAAFSV(配列番号:4);
ペプチドP59C13V−アミド(アミド):GQKGQVGPPGAAVRRAYAAFSV−アミド(配列番号:5);
ペプチドP59C13V(遊離酸):GQKGQVGPPGAAVRRAYAAFSV(配列番号:6);
ペプチドP74−アミド(アミド):GQKGQVGPPGAACRRYAAFSVGRRAYAAFSV−アミド(配列番号:7);
ペプチドP74(遊離酸):GQKGQVGPPGAACRRAYAAFSVGRRAYAAFSV(配列番号:8);
ペプチドP74C13V(アミド):GQKGQVGPPGAAVRRAYAAFSVGRRAYAAFSV−アミド(配列番号:9);
ペプチドP74C13V(遊離酸):GQKGQVGPPGAAVRRAYAAFSVGRRAYAAFSV(配列番号:10);
ペプチドP59SG(遊離酸Gly):AYAAFSVG(配列番号:11);
ペプチドP59−G(遊離酸Gly):GQKGQVGPPGAACRRAYAAFSVG(配列番号:12);
ペプチドP59C13V−G(遊離酸Gly):GQKGQVGPPGAAVRRAYAAFSVG(配列番号:13);
ペプチドP74−G(遊離酸Gly):GQKGQVGPPGAACRRAYAAFSVGRRAYAAFSVG(配列番号:14);
ペプチドP74C13V−G(遊離酸Gly):GQKGQVGPPGAAVRRAYAAFSVGRRAYAAFSVG(配列番号:15);
ペプチドP59−チンパンジー:GQKGQVGPPGAACQRAYAAFSVG(配列番号:20);
ペプチドP59−オランウータン:GQKGQVGPPGAPCQRAYAAFSVG(配列番号:21);
ペプチドP59−アカゲザル:GQKGQVGPPGAPCQRAYAAFSVG(配列番号:22);
ペプチドP59−雌ウシ:GQKGQAGLPGAQCPRAYAAFSVG(配列番号:23);
ペプチドP59−ニワトリ:GQKGQPGPQGHSCKQLYAAFSVG(配列番号:24);
ペプチドP59−C1QTNF1(ヒト):GQKGSMGAPGERCKSHYAAFSVG(配列番号:25);
ペプチドP59−ラット:GQKGSMGAPGDHCKSQYAAFSVG(配列番号:26);
これらペプチドは、RXFP1(LGR7)、RXFP2(LGR8)、RXFP3およびRXFP4からなる群より選択されるリラキシン関連GPCRのための、並びに/または、LRR(A10)含有GPCR:FSHR(LGR1)、LHCGR(LGR2)、TSHR(LGR3)、LGR4、LGR5、LGR6、LGR7(RXFPl)およびLGR8(RXFP2)に限定されないがこれらからなる群から選択されるLGRファミリーのGPCRの、リガンドである。
X1−X2−X3−X4−X5−X6−X7−X8−X9−X10−X11−X12−X13−X14−X15−X16−X17−X18−X19−X20−X21−X22−X23−X24−X25−X26−X27−X28−X29−X30−X31−X32−X33、
X1は、存在しないか、Gまたは小さな天然もしくは非天然アミノ酸であり;
X2は、存在しないか、Qまたは極性の天然もしくは非天然アミノ酸であり;
X3は、存在しないか、Kまたは塩基性の天然もしくは非天然アミノ酸であり;
X4は、存在しないか、Gまたは小さな天然もしくは非天然アミノ酸であり;
X5は、存在しないか、QまたはS、極性の天然もしくは非天然アミノ酸であり;
X6は、存在しないか、VまたはAまたはPまたはMまたは疎水性の天然もしくは非天然アミノ酸であり;
X7は、存在しないか、Gまたは小さな天然もしくは非天然アミノ酸であり;
X8は、存在しないか、PまたはLまたはA、天然もしくは非天然アミノ酸であり;
X9は、存在しないか、PまたはQ、天然もしくは非天然アミノ酸であり;
X10は、存在しないか、Gまたは小さな天然もしくは非天然アミノ酸であり;
X11は、存在しないか、AまたはHまたはEまたはDまたは、疎水性のもしくは小さなもしくは酸性の天然か非天然のアミノ酸であり;
X12は、存在しないか、AまたはPまたはQまたはSまたはRまたはHまたは、疎水性のもしくは小さな天然か非天然のアミノ酸であり;
X13は、存在しないか、CまたはVまたは疎水性の天然もしくは非天然アミノ酸であり;
X14は、存在しないか、RまたはKまたはQまたはPまたは、塩基性のもしくは極性の天然か非天然のアミノ酸であり;
X15は、存在しないか、RまたはQまたはSまたは、塩基性のもしくは極性の天然か非天然のアミノ酸であり;
X16は、存在しないか、AまたはLまたはHまたはQまたは、疎水性のもしくは小さな天然か非天然のアミノ酸であり;
X17は、存在しないか、Yまたは、疎水性のもしくは芳香族の天然か非天然のアミノ酸であり;
X18は、存在しないか、Aまたは、疎水性のもしくは小さな天然か非天然のアミノ酸であり;
X19は、存在しないか、Aまたは疎水性の小さな天然もしくは非天然アミノ酸であり;
X20は、存在しないか、Fまたは、疎水性のもしくは芳香族の天然か非天然のアミノ酸であり;
X21は、存在しないか、SまたはTまたは極性の天然もしくは非天然アミノ酸であり;
X22は、存在しないか、Vまたは疎水性の天然もしくは非天然アミノ酸であり;
X23は、存在しないか、Gまたは疎水性のもしくは小さな天然か非天然のアミノ酸であるか、またはアミドで置換され;
X24は、存在しないか、Rまたは塩基性の天然もしくは非天然アミノ酸であり;
X25は、存在しないか、Rまたは塩基性の天然もしくは非天然アミノ酸であり;
X26は、Aまたは疎水性のもしくは小さな天然か非天然のアミノ酸であり;
X27は、Yまたは疎水性のもしくは芳香族の天然か非天然のアミノ酸であり;
X28は、Aまたは疎水性のもしくは小さな天然か非天然のアミノ酸であり;
X29は、Aまたは疎水性のもしくは小さな天然か非天然のアミノ酸であり;
X30は、Fまたは疎水性の天然もしくは非天然アミノ酸であり;
X31は、SまたはTまたは極性の天然もしくは非天然アミノ酸であり;
X32は、Vまたは疎水性の天然もしくは非天然アミノ酸であり;
X33は、存在しないか、Gまたは疎水性のもしくは小さな天然か非天然のアミノ酸であるか、またはアミドで置換される)
のアミノ酸配列またはその薬剤的に許容可能な塩を含む。
ペプチドP−59S(アミド):AYAAFSV−アミド(配列番号:1);
ペプチドP−59S(遊離酸):AYAAFSV(配列番号:2);
ペプチドP59−アミド(アミド):GQKGQVGPPGAACRRAYAAFSV−アミド(配列番号:3);
ペプチドP59(遊離酸):GQKGQVGPPGAACRRAYAAFSV(配列番号:4);
ペプチドP59C13V−アミド(アミド):GQKGQVGPPGAAVRRAYAAFSV−アミド(配列番号:5);
ペプチドP59C13V(遊離酸):GQKGQVGPPGAAVRRAYAAFSV(配列番号:6);
ペプチドP74−アミド(アミド):GQKGQVGPPGAACRRAYAAFSVGRRAYAAFSVアミド(配列番号:7);
ペプチドP74(遊離酸):GQKGQVGPPGAACRRAYAAFSVGRRAYAAFSV(配列番号:8);
ペプチドP74C13V−アミド(アミド):GQKGQVGPPGAAVRRAYAAFSVGRRAYAAFSVアミド(配列番号:9);
ペプチドP74C13V(遊離酸):GQKGQVGPPGAAVRRAYAAFSVGRRAYAAFSV(配列番号:10);
ペプチドP59SG(遊離酸Gly):AYAAFSVG(配列番号:11);
ペプチドP59−G(遊離酸Gly):GQKGQVGPPGAACRRAYAAFSVG(配列番号:12);
ペプチドP59C13V−G(遊離酸Gly):GQKGQVGPPGAAVRRAYAAFSVG(配列番号:13);
ペプチドP74−G(遊離酸Gly):GQKGQVGPPGAACRRAYAAFSVGRRAYAAFSVG(配列番号:14);
ペプチドP74C13V−G(遊離酸Gly):GQKGQVGPPGAAVRRAYAAFSVGRRAYAAFSVG(配列番号:15);
ペプチドP59−チンパンジー:GQKGQVGPPGAACQRAYAAFSVG(配列番号:20);
ペプチドP59−オランウータン:GQKGQVGPPGAPCQRAYAAFSVG(配列番号:21);
ペプチドP59−アカゲザル:GQKGQVGPPGAPCQRAYAAFSVG(配列番号:22);
ペプチドP59−雌ウシ:GQKGQAGLPGAQCPRAYAAFSVG(配列番号:23);
ペプチドP59−ニワトリ:GQKGQPGPQGHSCKQLYAAFSVG(配列番号:24);
ペプチドP59−C1QTNFl1(ヒト):GQKGSMGAPGERCKSHYAAFSVG(配列番号:25);
ペプチドP59−ラット:GQKGSMGAPGDHCKSQYAAFSVG(配列番号:26)。
ペプチドP−59S−アミド(アミド):AYAAFSV−アミド(配列番号:1);
ペプチドP−59S(遊離酸):AYAAFSV(配列番号:2);
ペプチドP59−アミド(アミド):GQKGQVGPPGAACRRAYAAFSV−アミド(配列番号:3);
ペプチドP59(遊離酸):GQKGQVGPPGAACRRAYAAFSV(配列番号:4);
ペプチドP59C13V−アミド(アミド):GQKGQVGPPGAAVRRAYAAFSV−アミド(配列番号:5);
ペプチドP59C13V(遊離酸):GQKGQVGPPGAAVRRAYAAFSV(配列番号:6);
ペプチドP74−アミド(アミド):GQKGQVGPPGAACRRAYAAFSVGRRAYAAFSVアミド(配列番号:7);
ペプチドP74(遊離酸):GQKGQVGPPGAACRRAYAAFSVGRRAYAAFSV(配列番号:8);
ペプチドP74C13V−アミド(アミド):GQKGQVGPPGAAVRRAYAAFSVGRRAYAAFSVアミド(配列番号:9);
ペプチドP74C13V(遊離酸):GQKGQVGPPGAAVRRAYAAFSVGRRAYAAFSV(配列番号:10);
ペプチドP59SG(遊離酸Gly):AYAAFSVG(配列番号:11);
ペプチドP59−G(遊離酸Gly):GQKGQVGPPGAACRRAYAAFSVG(配列番号:12);
ペプチドP59C13V−G(遊離酸Gly):GQKGQVGPPGAAVRRAYAAFSVG(配列番号:13);
ペプチドP74−G(遊離酸Gly):GQKGQVGPPGAACRRAYAAFSVGRRAYAAFSVG(配列番号:14);
ペプチドP74C13V−G(遊離酸Gly):GQKGQVGPPGAAVRRAYAAFSVGRRAYAAFSVG(配列番号:15);
ペプチドP59−チンパンジー:GQKGQVGPPGAACQRAYAAFSVG(配列番号:20);
ペプチドP59−オランウータン:GQKGQVGPPGAPCQRAYAAFSVG(配列番号:21);
ペプチドP59−アカゲザル:GQKGQVGPPGAPCQRAYAAFSVG(配列番号:22);
ペプチドP59−雌ウシ:GQKGQAGLPGAQCPRAYAAFSVG(配列番号:23);
ペプチドP59−ニワトリ:GQKGQPGPQGHSCKQLYAAFSVG(配列番号:24);
ペプチドP59−C1QTNF1(ヒト):GQKGSMGAPGERCKSHYAAFSVG(配列番号:25);
ペプチドP59−ラット:GQKGSMGAPGDHCKSQYAAFSVG(配列番号:26)。
1.LGRファミリー:LGR1(FSHR)、LGR2(LHCGR)、LGR3(TSHR)、KGR4、LGR5、LGR6、LGR7(RXFP1)およびLGR8(RXFP2)を含むGPCRを包含する全てのLRRから成る。
2.リラキシン関連ファミリー:RXFP1(LGR7)、RXFP2(LGR8)、RXFP3(GPCR135)およびRXFP4(GPCR142)を含む全てのリラキシン活性化受容体から成る。
式Iは、以下の式の範囲内で表され、式中:
X1は、存在しないか、Gまたは小さな天然もしくは非天然アミノ酸であり;
X2は、存在しないか、Qまたは極性の天然もしくは非天然アミノ酸であり;
X3は、存在しないか、Kまたは塩基性の天然もしくは非天然アミノ酸であり;
X4は、存在しないか、Gまたは小さな天然もしくは非天然アミノ酸であり;
X5は、存在しないか、QまたはS、極性の天然もしくは非天然アミノ酸であり;
X6は、存在しないか、VまたはAまたはPまたはMまたは疎水性の天然もしくは非天然アミノ酸であり;
X7は、存在しないか、Gまたは小さな天然もしくは非天然アミノ酸であり;
X8は、存在しないか、PまたはLまたはA、天然もしくは非天然アミノ酸であり;
X9は、存在しないか、PまたはQ、天然もしくは非天然アミノ酸であり;
X10は、存在しないか、Gまたは小さな天然もしくは非天然アミノ酸であり;
X11は、存在しないか、AまたはHまたはEまたはDまたは、疎水性のもしくは小さなもしくは酸性の天然か非天然のアミノ酸であり;
X12は、存在しないか、AまたはPまたはQまたはSまたはRまたはHまたは、疎水性のもしくは小さな天然か非天然のアミノ酸であり;
X13は、存在しないか、CまたはVまたは疎水性の天然もしくは非天然アミノ酸であり;
X14は、存在しないか、RまたはKまたはQまたはPまたは、塩基性のもしくは極性の天然か非天然のアミノ酸であり;
X15は、存在しないか、RまたはQまたはSまたは、塩基性のもしくは極性の天然か非天然のアミノ酸であり;
X16は、存在しないか、AまたはLまたはHまたはQまたは、疎水性のもしくは小さな天然か非天然のアミノ酸であり;
X17は、存在しないか、Yまたは、疎水性のもしくは芳香族の天然か非天然のアミノ酸であり;
X18は、存在しないか、Aまたは、疎水性のもしくは小さな天然か非天然のアミノ酸であり;
X19は、存在しないか、Aまたは疎水性の小さな天然もしくは非天然アミノ酸であり;
X20は、存在しないか、Fまたは、疎水性のもしくは芳香族の天然か非天然のアミノ酸であり;
X21は、存在しないか、SまたはTまたは極性の天然もしくは非天然アミノ酸であり;
X22は、存在しないか、Vまたは疎水性の天然もしくは非天然アミノ酸であり;
X23は、存在しないか、Gまたは疎水性のもしくは小さな天然か非天然のアミノ酸であるか、またはアミドで置換され;
X24は、存在しないか、Rまたは塩基性の天然もしくは非天然アミノ酸であり;
X25は、存在しないか、Rまたは塩基性の天然もしくは非天然アミノ酸であり;
X26は、Aまたは疎水性のもしくは小さな天然か非天然のアミノ酸であり;
X27は、Yまたは疎水性のもしくは芳香族の天然か非天然のアミノ酸であり;
X28は、Aまたは疎水性のもしくは小さな天然か非天然のアミノ酸であり;
X29は、Aまたは疎水性のもしくは小さな天然か非天然のアミノ酸であり;
X30は、Fまたは疎水性の天然もしくは非天然アミノ酸であり;
X31は、SまたはTまたは極性の天然もしくは非天然アミノ酸であり;
X32は、Vまたは疎水性の天然もしくは非天然アミノ酸であり;
X33は、存在しないか、Gまたは疎水性のもしくは小さな天然か非天然のアミノ酸であるか、またはアミドで置換される;
化合物またはその薬剤的に許容可能な塩を含む。
ペプチドP59−S−アミド(アミド):AYAAFSV−アミド(配列番号:1);
ペプチドP59−SG(遊離酸Gly):AYAAFSV(配列番号:2);
ペプチドP59−アミド(アミド):GQKGQVGPPGAACRRAYAAFSV−アミド(配列番号:3);
ペプチドP59(遊離酸):GQKGQVGPPGAACRRAYAAFSV(配列番号:4);
ペプチドP59C13V−アミド(アミド):GQKGQVGPPGAAVRRAYAAFSV−アミド(配列番号:5);
ペプチドP59C13V(遊離酸):GQKGQVGPPGAAVRRAYAAFSV(配列番号:6);
ペプチドP74−アミド(アミド):GQKGQVGPPGAACRRAYAAFSVGRRAYAAFSV−アミド(配列番号:7);
ペプチドP74(遊離酸):GQKGQVGPPGAACRRAYAAFSVGRRAYAAFSV(配列番号:8);
ペプチドP74C13V(アミド):GQKGQVGPPGAAVRRAYAAFSVGRRAYAAFSV−アミド(配列番号:9);
ペプチドP74C13V(遊離酸):GQKGQVGPPGAAVRRAYAAFSVGRRAYAAFSV(配列番号:10);
ペプチドP59SG(遊離酸Gly):AYAAFSVG(配列番号:11);
ペプチドP59−G(遊離酸Gly):GQKGQVGPPGAACRRAYAAFSVG(配列番号:12);
ペプチドP59C13V−G(遊離酸Gly):GQKGQVGPPGAAVRRAYAAFSVG(配列番号:13);
ペプチドP74−G(遊離酸Gly):GQKGQVGPPGAACRRAYAAFSVGRRAYAAFSVG(配列番号:14);
ペプチドP74C13V−G(遊離酸Gly):GQKGQVGPPGAAVRRAYAAFSVGRRAYAAFSVG(配列番号:15);
ペプチドP59−チンパンジー:GQKGQVGPPGAACQRAYAAFSVG(配列番号:20);
ペプチドP59−オランウータン:GQKGQVGPPGAPCQRAYAAFSVG(配列番号:21);
ペプチドP59−アカゲザル:GQKGQVGPPGAPCQRAYAAFSVG(配列番号:22);
ペプチドP59−雌ウシ:GQKGQAGLPGAQCPRAYAAFSVG(配列番号:23);
ペプチドP59−ニワトリ:GQKGQPGPQGHSCKQLYAAFSVG(配列番号:24);
ペプチドP59−C1QTNF1(ヒト):GQKGSMGAPGERCKSHYAAFSVG(配列番号:25);
ペプチドP59−ラット:GQKGSMGAPGDHCKSQYAAFSVG(配列番号:26)のうちの1を含み、
この配列は、RXFP1(LGR7)、RXFP2(LGR8)、RXFP3(GPCR135)およびRXFP4(GPCR142)から成る群より選択されるリラキシン関連GPCR;および/またはLRRを含むGPCR:FSHR(LGR1)、LHCGR(LGR2)、TSHR(LGR3)、LGR4、LGR5、LGR6、LGR7(RXFP1)およびLGR8(RXFP2)から成る群より選択されるがこれらに限定されないLGRファミリーのGPCRに対するリガンドである。
融合タンパク質
免疫グロブリンの定常部を含む免疫グロブリンの一部と融合させることにより、本発明のペプチドから融合タンパク質が調製されてよい。さらに好ましくは該免疫グロブリンの一部は重鎖定常部を含み、該重鎖定常部は任意に、かつ、さらに好ましくはヒト重鎖定常部である。重鎖定常部は最も好ましくはIgG重鎖定常部であり、任意に、かつ最も好ましくはFc鎖であり、最も好ましくはCH2およびCH3ドメインを含むIgGFc断片である。いずれのIgGサブタイプも任意に用いられてよいが、IgG1サブタイプが好ましい。Fc鎖は任意に知られているか、または「野生型」Fc鎖、もしくは変異していてよい。変異の限定されない、説明的な、代表的な型は、2006年2月16日に公表され、ここに完全に説明されているかのように参照として取り込まれる米国特許出願公開第20060034852号に記載される。「Fc鎖」との語は、Fc断片のいずれの型もまた任意に含む。
本発明のペプチドが直鎖状分子の場合、化学修飾に感受性であるかまたは適した直鎖状分子の様々な点において、様々な官能基を配置することが可能である。官能基は直鎖型ペプチドの末端に付加できる。幾つかの実施形態によれば、官能基は、安定性、透過(細胞膜および/または組織関門を通した)、組織局在性、有効性における改善、減少されたクリアランス、減少された毒性、改善された選択性、改善された細胞ポンプによる排出への抵抗性などを含むがこれらに限定されない1以上の特性に関するペプチドの活性を改善する。便宜目的で、これに限定しようとするものではなく、本発明の組成物中に含まれる一配列の遊離N−末端は、該組成物のN−末端として名付けられ、かつ該配列のC−末端は該組成物のC−末端としてみなされるであろう。配列のC−末端またはN−末端のいずれか、または両方は、それぞれカルボン酸官能基またはアミン官能基に結合できる。
本発明の組成物中のアミノ酸は、「ペプチド模倣の有機成分」により、保存的および非保存的置換の両方として置換できる。これらの成分はまた「非天然アミノ酸」とも称され、アミノ酸残基、アミノ酸を任意に置換するか、またはペプチド内で欠失したアミノ酸の代わりにスペーサー基として働く。ペプチド模倣有機成分は任意にかつ好ましくは、置換されたアミノ酸と同様の立体的、電気的、または配置の特性を有し、このようなペプチド模倣物は重要な位置にあるアミノ酸を置換するために用いられ、保存的な置換とみなされる。しかしながらこのような類似性は必ずしも必要とされない。本発明の好ましい実施形態によれば、本発明の天然ペプチドタンパク質に比較して、組成物が少なくともその生理的活性を実質的に保持する1以上のペプチド模倣物が選択される。
本発明におけるペプチドのいずれの部分も任意に化学修飾、すなわち官能基を付加されてよい。例えば天然配列にみられるアミノ酸残基の側鎖は任意に修飾されてよい。しかしながら、アミノ酸残基の側鎖に加え、またはその代わりに、下記のように該タンパク質のその他の部分が代わりに任意に修飾されてよい。化学合成過程がそれに続く場合、例えば化学的に修飾されたアミノ酸の付加により、修飾は分子の合成の間に任意に行われてよい。しかしながらアミノ酸の化学修飾は、それが既に分子内に存在する場合(「in situ」修飾)にもまた可能である。
本発明のペプチドは、変化したグリコシル化のパターンを有するように修飾されてよい(すなわち本来の、または天然のグリコシル化パターンからの変化)。ここで用いられる「変化した」は、本来のタンパク質に1以上の炭水化物成分の欠失がみられること、および/または少なくとも一つのグリコシル化部位が付加されることを意味する。
本発明はまた、ここに開示される生物活性ペプチドまたは生物活性ペプチドの断片に対する抗体も含む。幾つかの実施形態によれば、生物活性ペプチドはGPCRリガンドである。
ペプチドP59−S−アミド(アミド):AYAAFSV−アミド(配列番号:1);
ペプチドP59−SG(遊離酸Gly):AYAAFSV(配列番号:2);
ペプチドP59−アミド(アミド):GQKGQVGPPGAACRRAYAAFSV−アミド(配列番号:3);
ペプチドP59(遊離酸):GQKGQVGPPGAACRRAYAAFSV(配列番号:4);
ペプチドP59C13V−アミド(アミド):GQKGQVGPPGAAVRRAYAAFSV−アミド(配列番号:5);
ペプチドP59C13V(遊離酸):GQKGQVGPPGAAVRRAYAAFSV(配列番号:6);
ペプチドP74−アミド(アミド):GQKGQVGPPGAACRRAYAAFSVGRRAYAAFSV−アミド(配列番号:7);
ペプチドP74(遊離酸):GQKGQVGPPGAACRRAYAAFSVGRRAYAAFSV(配列番号:8);
ペプチドP74C13V(アミド):GQKGQVGPPGAAVRRAYAAFSVGRRAYAAFSV−アミド(配列番号:9);
ペプチドP74C13V(遊離酸):GQKGQVGPPGAAVRRAYAAFSVGRRAYAAFSV(配列番号:10);
ペプチドP59SG(遊離酸Gly):AYAAFSVG(配列番号:11);
ペプチドP59−G(遊離酸Gly):GQKGQVGPPGAACRRAYAAFSVG(配列番号:12);
ペプチドP59C13V−G(遊離酸Gly):GQKGQVGPPGAAVRRAYAAFSVG(配列番号:13);
ペプチドP74−G(遊離酸Gly):GQKGQVGPPGAACRRAYAAFSVGRRAYAAFSVG(配列番号:14);
ペプチドP74C13V−G(遊離酸Gly):GQKGQVGPPGAAVRRAYAAFSVGRRAYAAFSVG(配列番号:15);
ペプチドP59−チンパンジー:GQKGQVGPPGAACQRAYAAFSVG(配列番号:20);
ペプチドP59−オランウータン:GQKGQVGPPGAPCQRAYAAFSVG(配列番号:21);
ペプチドP59−アカゲザル:GQKGQVGPPGAPCQRAYAAFSVG(配列番号:22);
ペプチドP59−雌ウシ:GQKGQAGLPGAQCPRAYAAFSVG(配列番号:23);
ペプチドP59−ニワトリ:GQKGQPGPQGHSCKQLYAAFSVG(配列番号:24);
ペプチドP59−C1QTNF1(ヒト):GQKGSMGAPGERCKSHYAAFSVG(配列番号:25);
ペプチドP59−ラット:GQKGSMGAPGDHCKSQYAAFSVG(配列番号:26)に対して産生される。
本発明のさらなる態様によれば、対象における上記の疾病、疾患または状態を治療する方法が提供される。
生物活性ペプチドリガンドは、ヒト患者への医薬組成物の投与に適した薬剤的に許容可能な担体において、典型的に提供される。当業者によって認識され得るように、担体は以下に述べるような投与経路、標的となる問題の位置、送達される薬物、薬物送達の時間経過などに基づいて選択されてよい。
薬物送達システムを設計するため、必要量の薬物を標的部位へ必要な期間、効果的かつ正確に送達するための様々な種類の高機能担体物質が開発されている。シクロデキストリン、生物分解性または非生物分解性重合体、リポソーム、エマルジョンである。ゲスト分子の物理的、化学的および生物学的特性を変化させる能力により、複数のエマルジョンがこの役割のための強力な候補である。重合体マイクロカプセル、マイクロ粒子、ナノ粒子、リポソームおよびエマルジョンを含むがこれらに限定されない、幾つかの薬物送達システムが存在する。これらの多くは、ポリ無水物およびポリヒドロキシ酸のような、合成生物分解性重合体から調製される。これらのシステムにおいて薬物は、生物内部で日、月、または年までの期間に、薬物の少量かつ制御された一日量を放出する重合体ミクロスフェアに取り込まれる。
「粘膜送達増強剤」は、水、塩および/または一般的な緩衝液、ならびに本発明の範囲内のペプチドを含む製剤(コントロール製剤)に添加したとき、最大血液、血清、または脳脊髄液濃度(Cmax)により、または濃度対時間のプロットにおける曲線下面積、AUCにより測定される、粘膜を横断するペプチド輸送の著しい増大を起こす製剤を産生する化学薬品およびその他の賦形剤として定義される。粘膜は鼻、口腔、腸、頬、気管支肺、膣、および直腸の粘膜表面を含み、かつ実際には外部と連絡する全ての体腔または経路を裏打ちする全ての粘液分泌膜を含む。
本発明は、1以上の粘膜送達増強剤および任意の単数または複数の持続放出増強剤と組み合わせた本発明の範囲内のペプチドを含む製剤の、改善した粘膜(例えば鼻の)送達を提供する。本発明の粘膜送達増強剤は、送達の効果的な増大、例えば粘膜に投与されたペプチドの治療活性を増強する最大血漿濃度(Cmax)の増大をもたらす。血漿およびCNS中のペプチドの治療活性に影響を及ぼす第2の因子は、滞留時間(RT)である。鼻腔内送達増強剤と組み合わせた持続放出増強剤は、ペプチドのCmaxを増大し、かつ滞留時間(RT)を増大する。持続放出増強剤をもたらす本発明の重合体送達ビヒクルおよびその他の薬剤ならびに方法、例えばポリエチレングリコール(PEG)をここに開示する。本発明の粘膜送達製剤および方法の範囲内で、粘膜送達のためペプチドはしばしば適切な担体またはビヒクルと組み合わせて、または協調的に投与される。ここで用いられる「担体」との語は、薬剤的に許容可能な固体または液体注入剤、希釈液または被包物質を意味する。水を含む液体担体は、酸性化剤、アルカリ化剤、抗微生物保存料、抗酸化剤、緩衝液、キレート剤、錯化剤、可溶化剤、保湿剤、溶媒、懸濁および/または粘度増強剤、等張化剤、湿潤剤、またはその他の生物適合性物質のような薬剤的に許容可能な添加剤を含むことができる。上のカテゴリーに収載した成分の作表はU.S.Pharmacopeia National Formulary,1857−1859,(1990)に見出すことができる。ここで用いられる「粘膜送達増強剤」は、ペプチドまたはその他の生物活性化合物の放出または溶解度(例えば製剤送達ビヒクルからの)、拡散率、透過能およびタイミング、取り込み、滞留時間、安定性、有効な半減期、ピークまたは持続濃度レベル、クリアランスおよびその他の望まれる粘膜送達特性(例えば送達部位、または血流もしくは中枢神経系のような活性の標的部位において測定されるものとして)を増強する薬剤を含む。本発明の特定の態様によれば、本発明のペプチドの協調的投与または組み合わせ製剤のための吸収促進剤は、ジメチルスルホキシド(DMSO)、ジメチルホルムアミド、エタノール、プロピレングリコール、および2−ピロリドンを含むがこれらに限定されない、親水性小分子から選択される。あるいは、長鎖の両親媒性分子、例えばジアシルメチルスルホキシド、アゾン、ラウリル硫酸ナトリウム、オレイン酸、および胆汁酸が、ペプチドの粘膜透過性を増強するために用いられてよい。さらなる態様によれば、界面活性剤(例えばポリソルベート)が、ペプチドの鼻腔内送達を増強する補助化合物、処理剤、または製剤添加剤として用いられる。DNSO、ポリエチレングリコール、およびエタノールのような薬剤が送達環境に十分な高濃度で存在していれば(例えば前投与または治療製剤内への取り込みによって)、粘膜の水層に進入し、その可溶化特性を変化させ、それによってビヒクルから粘膜へのペプチドの分配を増大させる。本発明の粘膜治療および予防組成物は、粘膜関門を横切るペプチドの吸収、拡散、または透過を促進する、いずれの適切な透過促進剤が追加されてよい。透過促進剤は、薬剤的に許容可能ないずれの促進剤であってもよい。
疎水性粘膜関門を横切る増強された送達のための生物活性薬剤(本発明のペプチドを含む)の輸送特性を改善するため、本発明は選択された生物活性薬剤またはここに述べる送達増強剤の電荷修飾のための技術および試薬もまた提供する。これについて、高分子の相対透過性は一般にその分配係数に関連する。分子のpKaおよび粘膜表面のpHに依存する分子のイオン化の程度は、分子の透過性にもまた影響を及ぼす。粘膜送達のための、本発明のペプチドを含む生物活性薬剤の浸透および分配は、活性剤または透過剤の電荷変化または電荷拡散により促進されてよく、これは例えば荷電官能基の変化により、活性剤が送達される送達ビヒクルまたは溶液のpHの変更により、または電荷もしくはpH変更試薬と活性剤との協調的投与により達成される。これらの一般的教示に一致して、本発明のペプチドを含む荷電高分子種の粘膜送達は、活性剤が実質的に非イオン化または中性の電気的荷電状態において粘膜表面に送達されるとき、実質的に改善される。
経粘膜製剤に含まれてよい別の賦形剤は分解酵素阻害剤である。生物活性薬剤を保護するために酵素活性を阻害するいずれの阻害剤も、本発明の組成物および方法中に有用に用いられてよい。生物活性タンパク質およびペプチドの保護のための有用な酵素阻害剤は、例えば大豆トリプシン阻害剤、膵臓トリプシン阻害剤、キモトリプシン阻害剤、ならびにジャガイモ(solanum tuberosum L.)塊茎から分離されたトリプシンおよびキモトリプシン阻害剤を含む。阻害剤は担体、例えば鼻粘膜に接触する剤形の表面にコートされた親水性ポリマーに取り込まれるかもしくは結合してよく、または生物活性薬剤との組み合わせ、もしくは別々に投与される(例えば前投与される)製剤において表面の表層に取り込まれる。本発明での使用のためのさらなる酵素阻害剤は、その効力および毒性の程度が異なる広範囲の非タンパク質阻害剤から選択される。以下にさらに詳細に述べるように、これらの補助剤のマトリックスもしくはその他の送達ビヒクルへの不動化、または化学的に修飾された類似体の開発は、それらが遭遇したときに毒性効果を減少または除去するために容易に実行され得る。候補となる広範囲な群の間で、本発明での使用のための酵素阻害剤は、強力で不可逆的なセリンプロテアーゼ(例えばトリプシンおよびキモトリプシン)阻害剤であるジイソプロピルフルオロリン酸(DFP)、およびフッ化フェニルメチルスルホニル(PMSF)のような有機リン阻害剤である。本発明の方法および組成物での使用のための酵素阻害剤のさらに別の型は、特定の治療化合物の酵素分解を阻害するアミノ酸および修飾アミノ酸である。
C1QT8に由来するP74、P59‐SおよびP59に関連する全ペプチド、仮定タンパク質(配列番号:19)またはそのオルソログもしくは相同配列を含有するコラーゲン反復:
>P60827 C1QT8_HUMAN 相補C1q腫瘍壊死因子関連タンパク質8‐Homo sapiens(ヒト)
MAAPALLLLALLLPVGAWPGLPRRPCVHCCRPAWPPGPYARVSDRDLWRGDLWRGLPRVRPTIDIEILKGEKGEAGVRGRAGRSGKEGPPGARGLQGRRGQKGQVGPPGAACRRAYAAFSVGRRAYAAFSVGRREGLHSSDHFQAVPFDTELVNLDGAFDLAAGRFLCTVPGVYFLSLNVHTWNYKETYLHIMLNRRPAAVLYAQPSERSVMQAQSLMLLLAAGDAVWVRMFQRDRDNAIYGEHGDLYITFSGHLVKPAAEL
ペプチドP59−S−アミド(アミド):AYAAFSV−アミド(配列番号:1);
ペプチドP59−SG(遊離酸Gly):AYAAFSV(配列番号:2);
ペプチドP59−アミド(アミド):GQKGQVGPPGAACRRAYAAFSV−アミド(配列番号:3);
ペプチドP59(遊離酸):GQKGQVGPPGAACRRAYAAFSV(配列番号:4);
ペプチドP59C13V−アミド(アミド):GQKGQVGPPGAAV*RRAYAAFSV−アミド(配列番号:5);
ペプチドP59C13V(遊離酸):GQKGQVGPPGAAV*RRAYAAFSV(配列番号:6);
ペプチドP74−アミド(アミド):GQKGQVGPPGAACRRAYAAFSVGRRAYAAFSV−アミド(配列番号:7);
ペプチドP74(遊離酸):GQKGQVGPPGAACRRAYAAFSVGRRAYAAFSV(配列番号:8);
ペプチドP74C13V(アミド):GQKGQVGPPGAAV*RRAYAAFSVGRRAYAAFSV−アミド(配列番号:9);
ペプチドP74C13V(遊離酸):GQKGQVGPPGAAV*RRAYAAFSVGRRAYAAFSV(配列番号:10);
ペプチドP59SG(遊離酸Gly):AYAAFSVG(配列番号:11);
ペプチドP59−G(遊離酸Gly):GQKGQVGPPGAACRRAYAAFSVG(配列番号:12);
ペプチドP59C13V−G(遊離酸Gly):GQKGQVGPPGAAV*RRAYAAFSVG(配列番号:13);
ペプチドP74−G(遊離酸Gly):GQKGQVGPPGAACRRAYAAFSVGRRAYAAFSVG(配列番号:14);
ペプチドP74C13V−G(遊離酸Gly):GQKGQVGPPGAAV*RRAYAAFSVGRRAYAAFSVG(配列番号:15);
ペプチドP59−チンパンジー:GQKGQVGPPGAACQRAYAAFSVG(配列番号:20);
ペプチドP59−オランウータン:GQKGQVGPPGAPCQRAYAAFSVG(配列番号:21);
ペプチドP59−アカゲザル:GQKGQVGPPGAPCQRAYAAFSVG(配列番号:22);
ペプチドP59−雌ウシ:GQKGQAGLPGAQCPRAYAAFSVG(配列番号:23);
ペプチドP59−ニワトリ:GQKGQPGPQGHSCKQLYAAFSVG(配列番号:24);
ペプチドP59−C1QTNF1(ヒト):GQKGSMGAPGERCKSHYAAFSVG(配列番号:25);
ペプチドP59−ラット:GQKGSMGAPGDHCKSQYAAFSVG(配列番号:26)、
*ペプチド内のCys残基を合成ペプチド中ではVで置換し、ペプチド中のシステイン残基での二量化を抑制するようにした。
LGR7(RXFP1)を一過性にトランスフェクトしたCHO‐K1細胞を10μMのフォルスコリンで10分間処理した後、H2リラキシン(ポジティブコントロールとして)、P59C13V(P59)(配列番号:6)またはP74C13V(P74)(配列番号:10)で、濃度を1nMから10μMに(図4A)、および3nMから100nMに(図4B)増加させながら負荷した。上記の通り、フォルスコリン存在下(Gi)(図4A)または非存在下(Gs)(図4B)にて、各濃度点でのcAMP濃度を定量した。
P59C13V(P59)(配列番号:6)、P59S‐アミド(P59S)(配列番号:1)、P59C13V‐アミド(P59アミド)(配列番号:5)およびP74C13V(P74)(配列番号:10)の活性を更に試験するために、以下のアッセイを行った。このアッセイは、P59C13V(P59)(配列番号:6)、P59S‐アミド(P59S)(配列番号:1)、P59C13V‐アミド(P59アミド)(配列番号:5)およびP74C13V(P74)(配列番号:10)のペプチドが、LGR7(RXFP1)またはLGR8(RXFP2)受容体をそれぞれ発現する安定なHEK−293T細胞株中でのH2リラキシンまたはINSL3活性を置換する能力を評価するために行われ、該アッセイはpCRE‐β‐galと共にそれぞれLGR7(RXFP1)またはLGR8(RXFP2)を発現する細胞株中で、これらのペプチドがcAMP活性を増加させる能力を評価することで行った。pCRE‐β‐galアッセイは標準的なもので、Howard Florey Institute(メルボルン、オーストラリア)にて確立されたものである(Halls ML,Bathgate RA,Summers RJ.−Comparison of signaling pathways activated by the relaxin family peptide receptors,RXFP1 and RXFP2,using reporter genes.J Pharmacol Exp Ther.2007Jan;320(1):281−90)。
ユウロピウムで標識したH2リラキシンまたはINSL3(H.Florey institute製)のLGR7またはLGR8をそれぞれ発現する安定なHEK−293T細胞株への結合と競合する、ペプチドP74C13V(配列番号:10)およびP59C13V(配列番号:6)の能力を試験することで、LGR7またはLGR8への既知のリガンドの結合と競合する、ペプチドP74C13V(配列番号:10)およびP59C13V(配列番号:6)の能力を試験した。
リラキシン関連ファミリーの受容体を活性化するペプチドの能力をACEA RT‐CESスクリーニングを使用して分析する方法
ACEA RT‐CESスクリーニングは、GPCRのための非侵襲性かつ非標識のアッセイであり、操作された細胞株および操作されていない細胞株の両方で使用できる。このアッセイは、細胞‐電極インピーダンスの使用に基づき、細胞形態の分毎の変化をリガンド依存性GPCR活性化の結果として測定し、これはNaichen Yu,et al.,Anal.Chem.,78(1),35−43,2006.10.1021/ac051695vS0003−2700(05)01695−1に記載されている。Rho、RacおよびCDC42を含むRhoファミリーの小GTPアーゼは、癌遺伝子、成長因子並びに接着媒介シグナル伝達経路のよく特徴付けられたエフェクターであり、GPCRのための重要なエフェクターとしては従来考えられていない。RhoファミリーのGTPアーゼは数多くの細胞プロセス、主としてはアクチン細胞骨格フレーム構造内の特定の構造の制御および維持に関与する。活性化されるRhoファミリーのGTPアーゼに応じて非常に特異的な様式で、GPCRがアクチン細胞骨格、従って細胞形態を調節することが示されている。アクチン細胞骨格の現在の見識は、動的(dynamic)で可塑的(plastic)なシステムのそれであり、これは細胞内シグナル伝達の反映および発現であり、細胞構成を維持するように設計された単なる静的構造ではない。GPCRはアクチン細胞骨格網に共役結合して極めて特定の形態学的変化を誘導するため、この情報をGPCRについての機能的かつ生物学的に関連性のある読み取り情報として役立てることが可能である。
他に断わりのない限り、ペプチドは固相ペプチド合成(SPPS)法によって合成し、樹脂から切断し、RP‐HPLCで精製した。ペプチドのアイデンティティーは質量分析法により検証した。RP‐HPLCで測定したペプチドの最終純度は>90%であった。ペプチドは0.1%BSAを含有する水中(DDW‐高純度)で希釈した。場合によっては、ペプチドをTris‐HCl緩衝液(pH8.2)に溶解させた。他の場合では、1%DMSOの添加または短時間の音波処理のいずれかが必要であった。全てのプレートを使用まで‐80℃で保管した。
液体窒素から細胞を新たに解凍し、以下のプロトコルに従って週2回1:10に継代培養した:
培地を除去して廃棄する。
0.25%(w/v)トリプシン‐0.53mM EDTA溶液で細胞層を短時間洗浄してトリプシン阻害物質を含有する微量の血清を全て除去する。
37℃で5分間、CO2加湿インキュベータにインキュベートする。
細胞層が分散するまで顕微鏡下で検査する。
10〜12mLの完全増殖培地を追加し、静かにピペットで吸引する。
細胞懸濁液から300μlのサンプルを取り出し、濃度、生存率および凝集速度を、CEDEXカウンタを使用してカウントする。
細胞を1200rpmで6分間遠心分離する。
所望の細胞濃度になるよう細胞を完全増殖培地中に再懸濁する。
全てのトランスフェクションは、FUGENE6試薬(Roche、Cat#11−814−443−001、使用期限:5/08)を使用して行った。
トランスフェクションの前日、2×106個のCHO−K1細胞を10mLの完全増殖培地を含むT75フラスコ中に播種した。トランスフェクション当日、FUGENE6トランスフェクション試薬を15分間室温でインキュベートして周囲温度まで温め、使用に先がけボルテックスして混合した。
このプロトコルでは、トランスフェクしたCHO‐K1細胞の播種、モニタリングおよび活性化のためにRCD96 E‐プレートデバイス(RCD96 E−plate device)(ACEA Biosciences Inc.)を使用した。
100μLの1mg/mlゼラチン(Fluka、Cat#48720)でE‐プレートウェルをコーティングした。ゼラチンは、8mg/mLで滅菌DDWに溶解させ、E‐プレートウェルへ添加する前にDDW中で1:8に希釈した。ゼラチンでコーティングしたプレートを、5%CO2の加湿雰囲気中、37℃で40分間インキュベートした。
トランスフェクとした細胞を播種する前に、80mlのSFM F12‐HAM培地をE‐プレートの各ウェルに添加し、バックグラウンドレベルを記録した。
播種の22〜26時間後(トランスフェクションの46〜52時間後)、記録した細胞指数(CI)に従って、活性化ペプチドの添加のために細胞を調製した。
10μMのスクリーニングした各ペプチドで、カルシトニン(1μM)をアッセイの内部ポジティブコントロール(internal positive control)(カルシトニンの受容体は、CHO−K1細胞により内因的に発現される)0.1%BSAをネガティブコントロールとして使用した。1μMのH2リラキシンをトランスフェクトした受容体についてのポジティブコントロールとして使用した。
0.03μM、0.1μM、0.3μM、1μM、3μMおよび10μMのスクリーニングした各ペプチドで、H2リラキシンをトランスフェクトした受容体についてのポジティブコントロールとして使用し、LGR7をトランスフェクトしたCHO−K1細胞を負荷した。
LGR7(RXFP1)受容体とLGR8(RXFP2)受容体を活性化するペプチドP74C13V(P74)(配列番号:10)およびP59C13V(P59)(配列番号:6)の能力を、ACEA細胞インピーダンスデバイスにおいて上記の通り検査した。以下の結果が得られた:
(H2)リラキシンとP74C13V(P74)(配列番号:10)の両方の、トランスフェクトしていないCHO−K1細胞中での用量反応活性化試験は、用量依存的な活性化を示さなかったが、最も高い濃度での中程度の活性化のみを示した(すなわち、P74C13Vについては10μMで、H2リラキシンについては1μM)(データは示さず)。
図20は、P59‐G(配列番号:12)の多重整列比較を示し、天然のヒト先駆体(C1QTNF8‐配列番号:19)の断片並びに、チンパンジー(配列番号:20)、オランウータン(配列番号:21)、アカゲザル(配列番号:22)、雌ウシ(配列番号:23)、ニワトリ(配列番号:24)およびラット(配列番号:26)を含む種々の生物に由来する相同配列を表している。この多重整列比較には、ヒトパラログであるC1QTNF1(配列番号:25)に由来する対応するペプチド配列も含まれる。見て分かる通り、N‐末端(4個のアミノ酸)およびC‐末端(7個のアミノ酸)が全種に同一である。量末端での切断部位もまた高度に保存されている(場合によってはKがRに置換される)。二量化のためにバリンで置換された中間のシステイン残基(C13)もまた高度に保存されている。
Claims (6)
- 精製されたペプチドであって:
ペプチドP59−S−アミド(アミド):AYAAFSV−アミド(配列番号:1);
ペプチドP59−S(遊離酸Gly):AYAAFSV(配列番号:2);
ペプチドP59−アミド(アミド):GQKGQVGPPGAACRRAYAAFSV−アミド(配列番号:3);
ペプチドP59(遊離酸):GQKGQVGPPGAACRRAYAAFSV(配列番号:4);
ペプチドP59C13V−アミド(アミド):GQKGQVGPPGAAVRRAYAAFSV−アミド(配列番号:5);
ペプチドP59C13V(遊離酸):GQKGQVGPPGAAVRRAYAAFSV(配列番号:6);
ペプチドP74−アミド(アミド):GQKGQVGPPGAACRRAYAAFSVGRRAYAAFSV−アミド(配列番号:7);
ペプチドP74(遊離酸):GQKGQVGPPGAACRRAYAAFSVGRRAYAAFSV(配列番号:8);
ペプチドP74C13V(アミド):GQKGQVGPPGAAVRRAYAAFSVGRRAYAAFSV−アミド(配列番号:9);
ペプチドP74C13V(遊離酸):GQKGQVGPPGAAVRRAYAAFSVGRRAYAAFSV(配列番号:10);
ペプチドP59SG(遊離酸Gly):AYAAFSVG(配列番号:11);
ペプチドP59−G(遊離酸Gly):GQKGQVGPPGAACRRAYAAFSVG(配列番号:12);
ペプチドP59C13V−G(遊離酸Gly):GQKGQVGPPGAAVRRAYAAFSVG(配列番号:13);
ペプチドP74−G(遊離酸Gly):GQKGQVGPPGAACRRAYAAFSVGRRAYAAFSVG(配列番号:14);
ペプチドP74C13V−G(遊離酸Gly):GQKGQVGPPGAAVRRAYAAFSVGRRAYAAFSVG(配列番号:15);
ペプチドP59−チンパンジー:GQKGQVGPPGAACQRAYAAFSVG(配列番号:20);
ペプチドP59−オランウータン:GQKGQVGPPGAPCQRAYAAFSVG(配列番号:21);
ペプチドP59−アカゲザル:GQKGQVGPPGAPCQRAYAAFSVG(配列番号:22);
ペプチドP59−雌ウシ:GQKGQAGLPGAQCPRAYAAFSVG(配列番号:23);
ペプチドP59−ニワトリ:GQKGQPGPQGHSCKQLYAAFSVG(配列番号:24);
ペプチドP59−C1QTNF1(ヒト):GQKGSMGAPGERCKSHYAAFSVG(配列番号:25);
ペプチドP59−ラット:GQKGSMGAPGDHCKSQYAAFSVG(配列番号:26);
からなる群から選択される配列を有することを特徴とするペプチド。 - 前記ペプチドが第二のペプチドまたはポリペプチドに接合または融合されていることを特徴とする請求項1に記載のペプチド。
- 請求項1または2に記載のペプチドと薬剤的に許容可能な担体とを含むことを特徴とする医薬組成物。
- 請求項1または2に記載のペプチドに選択的に結合することを特徴とする抗体。
- 前記抗体がモノクローナル抗体であることを特徴とする請求項4に記載の抗体。
- 前記抗体が検出可能な標識、放射性標識、酵素、蛍光標識、発光標識、生物発光標識もしくは治療薬に接合または結合されていることを特徴とする請求項5に記載の抗体。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95937007P | 2007-07-12 | 2007-07-12 | |
US60/959,370 | 2007-07-12 | ||
PCT/IB2008/002447 WO2009007848A2 (en) | 2007-07-12 | 2008-07-11 | Bioactive peptides and method of using same |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010532988A JP2010532988A (ja) | 2010-10-21 |
JP2010532988A5 JP2010532988A5 (ja) | 2012-05-24 |
JP5355561B2 true JP5355561B2 (ja) | 2013-11-27 |
Family
ID=40229171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010515627A Expired - Fee Related JP5355561B2 (ja) | 2007-07-12 | 2008-07-11 | 生物活性ペプチドおよびその使用方法 |
Country Status (7)
Country | Link |
---|---|
US (3) | US8492329B2 (ja) |
EP (1) | EP2167534B1 (ja) |
JP (1) | JP5355561B2 (ja) |
AU (1) | AU2008273813B2 (ja) |
CA (1) | CA2693651A1 (ja) |
IL (1) | IL203221A (ja) |
WO (1) | WO2009007848A2 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7878978B2 (en) | 2004-03-18 | 2011-02-01 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Use of relaxin to increase arterial compliance |
WO2009007848A2 (en) * | 2007-07-12 | 2009-01-15 | Compugen Ltd. | Bioactive peptides and method of using same |
CA2724540C (en) | 2008-05-16 | 2014-07-08 | Corthera, Inc. | Treating dyspnea associated with acute heart failure with relaxin |
WO2009140657A2 (en) | 2008-05-16 | 2009-11-19 | Corthera, Inc. | Method of treating chronic heart failure |
ES2929283T3 (es) | 2012-05-04 | 2022-11-28 | Us Health | Moduladores del receptor de relaxina 1 |
WO2013188681A1 (en) | 2012-06-14 | 2013-12-19 | Microvention, Inc. | Polymeric treatment compositions |
US20140081659A1 (en) | 2012-09-17 | 2014-03-20 | Depuy Orthopaedics, Inc. | Systems and methods for surgical and interventional planning, support, post-operative follow-up, and functional recovery tracking |
BR112015008245B1 (pt) | 2012-10-15 | 2022-09-27 | Microvention, Inc | Composições poliméricas de tratamento |
US9907833B2 (en) | 2013-07-25 | 2018-03-06 | University Of Florida Research Foundation, Incorporated | Use of relaxin to treat placental syndromes |
US10368874B2 (en) | 2016-08-26 | 2019-08-06 | Microvention, Inc. | Embolic compositions |
EP3369743A1 (en) * | 2017-03-01 | 2018-09-05 | advanceCOR GmbH | Cyclic peptides for the treatment of graves' disease |
EP3694422A4 (en) | 2017-10-09 | 2021-06-30 | Microvention, Inc. | EMBOLIC RADIOACTIVE LIQUID |
CN115867648A (zh) * | 2020-02-14 | 2023-03-28 | 西北大学 | 将用于遗传密码重编程的化学底物扩展至包括长链碳和环状氨基酸 |
WO2023154197A1 (en) * | 2022-02-10 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fused diazepines as agonists of the insulin-like 3 (insl3) peptide receptor rxfp2 and methods of use thereof |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3485206A (en) | 1967-09-06 | 1969-12-23 | Smrt Thomas John | Marking device |
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
US4078052A (en) | 1976-06-30 | 1978-03-07 | The United States Of America As Represented By The Secretary Of Health, Education And Welfare | Large unilamellar vesicles (LUV) and method of preparing same |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
CH624011A5 (ja) | 1977-08-05 | 1981-07-15 | Battelle Memorial Institute | |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
IT1111367B (it) | 1978-11-17 | 1986-01-13 | Serono Ist Farm | Processo per la preparazione estemporanea di liposomi e liposomi cosi' ottenuti |
US4310506A (en) | 1979-02-22 | 1982-01-12 | California Institute Of Technology | Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species |
US4394372A (en) | 1980-12-22 | 1983-07-19 | The Procter & Gamble Company | Process for making lipid membrane structures |
FR2521565B1 (fr) | 1982-02-17 | 1985-07-05 | Dior Sa Parfums Christian | Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees |
US4522803A (en) | 1983-02-04 | 1985-06-11 | The Liposome Company, Inc. | Stable plurilamellar vesicles, their preparation and use |
US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4552803A (en) | 1983-01-28 | 1985-11-12 | Pearson Glenn A | Fire retardant powders and methods |
US4588578A (en) | 1983-08-08 | 1986-05-13 | The Liposome Company, Inc. | Lipid vesicles prepared in a monophase |
US5169637A (en) | 1983-03-24 | 1992-12-08 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
US5030453A (en) | 1983-03-24 | 1991-07-09 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5008050A (en) | 1984-06-20 | 1991-04-16 | The Liposome Company, Inc. | Extrusion technique for producing unilamellar vesicles |
US5059421A (en) | 1985-07-26 | 1991-10-22 | The Liposome Company, Inc. | Preparation of targeted liposome systems of a defined size distribution |
US4975282A (en) | 1985-06-26 | 1990-12-04 | The Liposome Company, Inc. | Multilamellar liposomes having improved trapping efficiencies |
EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
GB9206861D0 (en) * | 1992-03-28 | 1992-05-13 | Univ Manchester | Wound healing and treatment of fibrotic disorders |
US20030220258A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of ischemic events |
GB9813100D0 (en) | 1998-06-18 | 1998-08-19 | Secr Defence | Method of forming liposomes |
WO2000046381A1 (en) * | 1999-02-04 | 2000-08-10 | University Of Georgia Research Foundation, Inc. | Recombinant expression of heterologous nucleic acids in protozoa |
US20050042719A1 (en) | 1999-05-27 | 2005-02-24 | Zymogenetics, Inc. | Adipocyte complement related protein homolog zacrp5 |
WO2000073444A1 (en) * | 1999-05-27 | 2000-12-07 | Zymogenetics, Inc. | Adipocyte complement related protein homolog zacrp5 |
EP1814573B1 (en) | 2004-10-29 | 2016-03-09 | ratiopharm GmbH | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
PT1812031E (pt) | 2004-11-01 | 2015-10-01 | Univ California | Composições e métodos para modificação de biomoléculas |
WO2009007848A2 (en) * | 2007-07-12 | 2009-01-15 | Compugen Ltd. | Bioactive peptides and method of using same |
-
2008
- 2008-07-11 WO PCT/IB2008/002447 patent/WO2009007848A2/en active Application Filing
- 2008-07-11 EP EP08826161A patent/EP2167534B1/en not_active Not-in-force
- 2008-07-11 JP JP2010515627A patent/JP5355561B2/ja not_active Expired - Fee Related
- 2008-07-11 US US12/668,712 patent/US8492329B2/en not_active Expired - Fee Related
- 2008-07-11 AU AU2008273813A patent/AU2008273813B2/en not_active Ceased
- 2008-07-11 CA CA2693651A patent/CA2693651A1/en not_active Abandoned
-
2010
- 2010-01-10 IL IL203221A patent/IL203221A/en not_active IP Right Cessation
-
2013
- 2013-06-21 US US13/923,690 patent/US8987191B2/en not_active Expired - Fee Related
-
2015
- 2015-02-23 US US14/628,586 patent/US20150307572A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2167534A2 (en) | 2010-03-31 |
AU2008273813B2 (en) | 2013-06-13 |
AU2008273813A1 (en) | 2009-01-15 |
EP2167534B1 (en) | 2012-07-04 |
WO2009007848A3 (en) | 2009-06-25 |
US8492329B2 (en) | 2013-07-23 |
IL203221A (en) | 2015-03-31 |
WO2009007848A2 (en) | 2009-01-15 |
US20110177998A1 (en) | 2011-07-21 |
CA2693651A1 (en) | 2009-01-15 |
US20150307572A1 (en) | 2015-10-29 |
JP2010532988A (ja) | 2010-10-21 |
US8987191B2 (en) | 2015-03-24 |
US20140005097A1 (en) | 2014-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5355561B2 (ja) | 生物活性ペプチドおよびその使用方法 | |
JP5502480B2 (ja) | 生物活性ペプチド及びその使用方法 | |
JP6748155B2 (ja) | 線維症抑制活性を有するペプチド及びこれを含む組成物 | |
US7186694B2 (en) | Leptin-related peptides | |
CN101693736B (zh) | 新的肽 | |
CA2560174A1 (en) | Y4 selective receptor agonists for therapeutic interventions | |
JP6883048B2 (ja) | 前立腺癌の進行を予防または緩和する小型神経糸ペプチド | |
JP2011528566A (ja) | アンジオポエチン由来ペプチド | |
US20090186811A1 (en) | Y2 Selective Receptor Agonists for Therapeutic Interventions | |
CA2559838A1 (en) | Y2 selective receptor agonists for therapeutic interventions | |
US7208572B2 (en) | Leptin-related peptides | |
KR20050090420A (ko) | 메타스틴 유도체 및 이의 용도 | |
WO2006041205A1 (ja) | 血管形成促進剤 | |
US8980843B2 (en) | Leptin agonist and methods of use | |
US8470772B2 (en) | Leptin agonist and methods of use | |
US7217808B2 (en) | RFRP-3 and DNA thereof | |
TWI300414B (en) | Modified peptide yy and conjugates thereof | |
JP6768140B2 (ja) | 急性尿閉の発生を予防または低減させる方法 | |
JP2006508646A (ja) | PTHrP由来の平滑筋増殖モジュレータ | |
US20040152634A1 (en) | Chemokine antagonists and uses thereof | |
WO2023183667A1 (en) | Urokinase-type plasminogen activator receptor binding peptides and methods of use | |
JP2002233386A (ja) | Rfrp含有プロラクチン分泌調節剤 | |
JP2000159795A (ja) | ペプチド誘導体 | |
JP2003174889A (ja) | 新規rfrp−3およびそのdna |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110613 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110613 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120319 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20120510 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20120516 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130423 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130722 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130725 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130729 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130820 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130827 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |